P-gp-IN-32
P-gp-IN-32 is a P-glycoprotein (P-gp) inhibitor. P-gp-IN-32 exhibits low cytotoxicity and potent multidrug resistance (MDR) reversal activity against Doxorubicin (HY-15142A) in MCF7/ADR cells (IC50 = 0.11 μM, reversal fold (RF) = 215.9). P-gp-IN-32 can bind to P-gp directly, induce a conformation change of P-gp and inhibit the efflux function. P-gp-IN-32 can be used for the research of cancer, such as breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 2918249-59-7
- Formula: C35H34N2O5
- Molecular Weight:562.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
P-gp-IN-32 (Compound BP3p) (5 μM) shows growth inhibition rates below 25% in both MCF-7 and MCF-7/ADR cells[1].
P-gp-IN-32 has a RF of 215.9 combined with Doxorubicin (HY-15142A) (IC50 of 0.11 μM) in MCF-7/ADR cells[1].
P-gp-IN-32 (2.5-5 μM, 4 h) increases Rhodamine 123 accumulation in MCF-7/ADR cells in a dose-dependent manner[1].
P-gp-IN-32 (0.5-5 μM, 48 h) has no significant effect on P-gp expression in MCF-7/ADR cells[1].
P-gp-IN-32 (50 μM) enhances UIC-2 antibody (HY-P990196) binding to P-gp in MCF-7/ADR cells[1].
P-gp-IN-32 (5 μM, 5 days) reduces the volume of MCF-7/ADR 3D tumor spheroids combined with Doxorubicin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7/ADR cells
-
Concentration:0.5, 2.5 and 5 μM
-
Incubation Time:48 h
-
Result:Did not reduce P-gp expression.
Chemical Information
-
CAS No. 2918249-59-7
-
Molecular Weight 562.65
-
Formula C35H34N2O5
-
SMILES
COC1=CC(C2=CC3=C(N(C(C(N4CCC5=C(C4)C=C(C(OC)=C5)OC)=O)=C3)CC6=CC=C(C=C6)OC)C=C2)=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)